|
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update. |
|
|
No Relationships to Disclose |
|
|
Employment - Caris Life Sciences; Indivumed |
|
Honoraria - Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Speakers' Bureau - Amgen; Bayer/Onyx; Merck; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; Genentech/Roche; Merck |
Speakers' Bureau - bms; Eisai; Exelixis |
Research Funding - Genentech; Merck |
|
|
|
Stock and Other Ownership Interests - Apple (I) |
Honoraria - Rafael Pharmaceuticals |
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; HalioDx |
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst) |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - ERYTECH Pharma |
Leadership - ERYTECH Pharma |
Stock and Other Ownership Interests - ERYTECH Pharma |
Travel, Accommodations, Expenses - ERYTECH Pharma |
|
|
Consulting or Advisory Role - Celgene; Ipsen; Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Daiichi Sankyo/Astra Zeneca; Taiho Pharmaceutical |